Ayisha Sharma

Aldeyra Therapeutics reports Phase 3 success with reproxalap for dry eye disease, plans third FDA filing after previous rejections. AbbVie partnership remains intact.

Merck KGaA said Monday it has inked a “definitive agreement” to acquire Pfizer spinout SpringWorks Therapeutics for an equity value of around $3.9 billion, rounding off several months of negotiations.

Sanofi's amlitelimab fails Phase 2 asthma trial at highest dose, but company sees path forward based on medium dose results in specific patient subgroup

Merck licenses Cyprumed's oral drug delivery platform in $493M deal to develop oral peptide formulations, potentially for GLP-1 drugs.

DHL Group investing €2B in healthcare/life sciences, AGC Biologics adds bioreactors in Japan, OXB reports revenue growth, plus updates from Sai Life Sciences, Curium, SHINE, Lonza & Asahi Kasei.

Novo Nordisk invests $1.05B in Brazil factory to boost GLP-1 drug production, including Wegovy and Ozempic, creating 600 jobs by 2028 in Montes Claros.

Cartesian Therapeutics reports sustained benefits of Descartes-08 CAR-T therapy in generalized myasthenia gravis patients, with 33% achieving minimum symptom expression at 12 months.

Corcept Therapeutics’ oral glucocorticoid receptor antagonist has improved survival outcomes in a late-stage test in patients with a challenging form of ovarian cancer, sending its shares up 76% at market open on Monday.

Axsome Therapeutics said the lower dose of its sleep disorder drug Sunosi met the primary endpoint in a late-stage test of adults with ADHD. But Wall Street analysts noted that less impressive results for its higher dose leave room for uncertainty about the company's label expansion prospects.

Roche has forged a multiyear partnership with Oxford BioTherapeutics to find new targets for antibody-based cancer treatments with an upfront payment of $36 million.

AstraZeneca is fine-tuning plans for a Phase 3 study for its B7-H4-targeting ADC after the drug produced encouraging response and survival results in endometrial cancer patients enrolled in an early study.

Amgen has shared additional Phase 3 data for its rare disease drug Uplizna in myasthenia gravis, bolstering the company’s case for label expansion before a planned FDA filing this quarter.

Merck has opened a new vaccine manufacturing plant at its existing site in Durham, NC, which will make a shot that is an important part of the bladder cancer treatment paradigm.

Companies report dermatology drug progress at AAD meeting: Amgen/Kyowa's rocatinlimab for eczema, BMS's Sotyktu for psoriatic arthritis, J&J's icotrokinra & Alumis's ESK-001 for psoriasis.

Persica Pharmaceuticals reports positive Phase 1b results for PP353, a two-dose antibiotic combining linezolid and iohexol, in treating chronic back pain with Modic Type 1 changes.

Epitopea has inked a license and research collaboration with Merck to discover new tumor-specific antigens from so-called “dark matter” DNA, which are parts of the genome that are thought not ...

AlgoTherapeutix’s topical non-opioid drug has flunked a mid-stage trial in chemotherapy-induced pain due to a stronger-than-expected placebo arm, but the company is still determined to find a path forward.

Bristol Myers Squibb's Opdualag (relatlimab/Opdivo) fails Phase 3 melanoma trial, adding to mixed results for LAG-3/PD-1 targeting immunotherapies.

Leaked Pfizer Phase 1 trial shows mevrometostat plus Xtandi reduced prostate cancer progression risk by 49%. Data sparked interest in Oric Pharmaceuticals' similar drug candidate.

The Mitsubishi Chemical Group is selling its centuries-old pharmaceutical business to Bain Capital in a carve-out worth about $3.3 billion.